NCT00544882View on ClinicalTrials.gov

A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Healthy
Interventions
DRUG

DR-1021

Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.

DRUG

Mircette®

Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.

DRUG

Kariva®

Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.

Trial Locations (4)

19114

Duramed Investigational Site, Philadelphia

43213

Duramed Investigational Site, Columbus

98105

Duramed Investigational Site, Seattle

08648

Duramed Investigational Site, Lawrenceville

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00544882 - A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021 | Biotech Hunter | Biotech Hunter